Diagnosis and treatment of adults with scalp psoriasis

Renton, Carla

doi:10.7748/ns2014.02.28.26.35.e8335

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficiency of transdermal drug absorption of w/o NEs is promoted through skin appendages via increasing the solubility of drugs and generating a greater concentration gradient between NEs and the skin ( Wu et al, 2001 ). Scalp psoriasis is an intractable medical problem, conventional therapies for which rely on long-term topical corticosteroid administration ( Turpeinen, 1989 ; Renton, 2014 ). To avoid the side effects of topical corticosteroids, Langasco et al formulated a Clobitasol Propionate (CP)-loaded w/o NEs system.…”

Section: Nanoparticlesmentioning

confidence: 99%

Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis

Qin

Dai

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated skin disorder involving hyperproliferation of the keratinocytes in the epidermis. As complex as its pathophysiology, the optimal treatment for psoriasis remains unsatisfactorily addressed. Though systemic administration of biological agents has made an impressive stride in moderate-to-severe psoriasis, a considerable portion of psoriatic conditions were left unresolved, mainly due to adverse effects from systemic drug administration or insufficient drug delivery across a highly packed stratum corneum via topical therapies. Along with the advances in nanotechnologies, the incorporation of nanomaterials as topical drug carriers opens an obvious prospect for the development of antipsoriatic topicals. Hence, this review aims to distinguish the benefits and weaknesses of individual nanostructures when applied as topical antipsoriatics in preclinical psoriatic models. In view of specific features of each nanostructure, we propose that a proper combination of distinctive nanomaterials according to the physicochemical properties of loaded drugs and clinical features of psoriatic patients is becoming a promising option that potentially drives the translation of nanomaterials from bench to bedside with improved transdermal drug delivery and consequently therapeutic effects.

show abstract

Section: Nanoparticlesmentioning

confidence: 99%

Transdermal Delivery of Therapeutic Compounds With Nanotechnological Approaches in Psoriasis

Qin

Dai

et al. 2022

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

show abstract

“…Certain clinical symptoms associated with this disorder are plaque, psoriasis, inverse psoriasis, Psoriasis vulgaris, palmoplantar psoriasis, erythrodermic psoriasis, pustular psoriasis and scalp psoriasis. [7][8][9][10] The entire skin surface of the body can also be affected. 11 Normal skin has a 30-day life cycle, but psoriasis has a 1.5-3-day life cycle.…”

mentioning

confidence: 99%

Bio-Evaluation, In-Vitro and In-Vivo Anti-Inflammatory Activity, Therapeutic Efficacy, and Genotoxicity of the Potentials of the Green Seaweed Valoniopsis Pachynema using Zebra Fish Larvae (Danio Rerio) as an Animal Model

Bhuvaneshwari.¹,

P²

2023

Pharmacogn J.

View full text Add to dashboard Cite

major component of the host's defense against many harmful agents, such as the invasion of foreign pathogens, physical injury, and other hostile immunological reactions, is regarded to be inflammation in general. 2,3 However, persistent, arthritis, rheumatoid, asthma, multiple sclerosis, inflammatory bowel disease, diabetes, cancer and psoriasis are only a few of the disorders that can be triggered by excessive or protracted inflammation. 4 Among these diseases, Psoriasis is one of the most frequent non-pathogenic skin conditions that have been identified so far. Psoriasis is a complex and multifaceted chronic inflammatory skin disease brought on by a confluence of hereditary and environmental factors. 5 About 2-3% of the inhabitants worldwide have psoriasis. Psoriasis is characterised by telangiectasia in the dermal papillae, hyperproliferation of keratinocytes, and recruitment of inflammatory cells to the epidermis. 6 Psoriasis is said to be caused because of the traumatic, environmental, or pharmacological stimuli that cause abnormal interaction among keratinocytes and various types of immune cell, results in exposed increase of pro-proliferative and inflammatory circuits in susceptible individuals. Certain clinical symptoms associated with this disorder are plaque, psoriasis, inverse psoriasis, Psoriasis vulgaris, palmoplantar psoriasis, erythrodermic psoriasis, pustular psoriasis and scalp psoriasis. [7][8][9][10] The entire skin surface of the body can also be affected. 11 Normal skin has a 30-day life cycle, but psoriasis has a 1.5-3-day life cycle. Nails and skin are frequently affected by psoriasis. Patients with psoriasis may also have concomitant conditions such as obesity, psoriatic arthritis, diabetes, metabolic syndrome, and cardiovascular diseases. 12 Consequently, it is also referred to as a T-cell mediated autoimmune illness. Interleukins (ILs), tumour necrosis factor (TNF-), and interferon-(IFN-) levels of inflammatory cytokines increase modestly in systemic circulation, but mostly in the dermis. Vascular-Endothelial Growth-Factor (VEGF) is created by mast cells, keratinocytes, and macrophages as a result of elevated levels of cytokines and other inflammatory mediators. New blood vessels are created as a result, increasing blood flow. According to recent research, there are 25 genetic variations that cause psoriasis. The cause of psoriasis is immune system activation, and the psoriasiscausing gene has been found. This could give precise and effective treatments to treat psoriasis. 13

show abstract